Granules India in focus after USFDA inspection ends with eleven observations

what happened

According to TradingView, Granules India's shares may attract attention on November 2 after the US Food and Drug Administration completed a current Good Manufacturing Practice inspection of its finished dosage facility in Gagillapur, Hyderabad. The check ran from October 19 to October 30, 2026, and ended with a Form FDA 483 listing eleven observations. It is the first USFDA visit to the site since a Warning Letter issued on February 26, 2025.

The company said none of the findings concern data integrity or cross-contamination. They cover investigations, change control, process and equipment qualification, visual-inspection controls and documentation. Granules added that manufacturing and distribution from the site are not affected, and it will send a full response to the agency within 15 business days.

Chairman and Managing Director Krishna Prasad Chigurupati said the inspection “progressed constructively” and that the observations can be fully addressed through responses and corrective and preventive actions. The board also meets on November 2, 2026 to approve unaudited results for the quarter and half-year ended September 30, 2026. The stock closed the previous session at Rs 839.55, up 0.35 percent, and sits 8.95 percent below its 52-week high of Rs 922.10.

why it matters

For investors, the key question is whether the observations delay the site's return to unrestricted status or add regulatory costs. The company's statement that production is unaffected limits the immediate risk, while the results the board considers the same day will give a clearer picture of the business.

tags

instruments